Addressing Unmet Needs for Localized or Targeted Delivery

Printer-friendly version

An increasing proportion of injectable drugs in development require novel delivery systems to enable their transition from the bench-top to the clinic and onto commercial success. There are also instances where conventional device solutions have been imposed on therapies, potentially resulting in harmful or sub-optimal outcomes to the patient.

These unmet, underappreciated and emerging needs create significant opportunities for the development of specialized delivery systems that can enable or enhance the delivery of novel drugs.

Localized or targeted delivery systems are becoming increasingly preferred for use with drug delivery applications where it is desirable to minimize unwanted systemic effects of the drug, or to help overcome transport barriers posed by the human anatomy. Modifications to the formulation or the design of the drug molecule are not sufficient for specialized therapies, which can require extremely accurate and precise systems for delivery in order to maximize clinical efficacy.

Whereas standard devices can be sufficient for common routes of administration such as intravenous, subcutaneous and intramuscular injection, they can fall well short of attaining desired clinical outcomes when used with targeted delivery drugs requiring intravitreal, intra-tumoral, intra-articular or other new or novel routes of administration.

Two particular pharmaceutical areas with emerging or unmet needs being addressed by Unilife is the localized or targeted delivery of microliter sized doses and drug depots in formats such as solids, powders, microspheres, rods or gels. Unilife devices such as the Ocu-ject™, Micro-ject™ and Depot-ject™ represent revolutionary technologies that have the potential to enable or enhance the clinical development and commercial success of a range of novel therapies.

As with other technologies developed by Unilife, these intraocular and specialized devices have been designed for seamless integration with standard pharmaceutical drug filling and finishing systems utilizing well understood materials in the fluid path.